Study: Post-ACA healthcare spending could fall $2.6 trillion below projections

The U.S. is on pace to spend about $2.6 trillion less on healthcare between 2014 and 2019 than what was originally forecast by CMS in 2010 after the Affordable Care Act was signed into law, according to a new study by the Urban Institute and funded by the Robert Wood Johnson Foundation (RWJF).

It’s a dramatic shift from the overall projections, which estimated healthcare spending would increase by $577 million between 2014 and 2019, largely due to the increased costs of expanding health coverage.

While some of the reduction could be attributed to certain policies, such as the 2012 Supreme Court decision saying states couldn’t be required to expand Medicaid or budget sequestration, the study largely credits a “historic slowdown” in healthcare spending growth.

“There are many potential drivers of the recent slowdown in spending growth rates, and no one can be sure how MACRA may impact spending going forward,” Kathy Hempstead, PhD, senior adviser to the vice president of the Robert Wood Johnson Foundation, said in a statement. “If this healthcare spending growth slowdown continues, spending will be trillions less before the end of the decade.”

The lion’s share of the reductions in the new forecast would come from Medicaid spending, which is projected to be $1 trillion less than what was estimated in 2010, likely due to some states not expanding eligibility.

Medicare spending is projected to drop by $455 billion in the 2015 projection, which incorporates the 2015 Medicare Access and CHIP Reauthorization Act (MACRA) and the end of the sustainable growth rate formula.

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.